Table 1

Clinicopathological features of patients with AITL-developed secondary EBV-associated B cell lymphoma described in present and previous reports

caseNo.

Authors (yr.)

Age/sex

Tumor site

Interval (mo)

Histotype of BCL*

Treatment

Clinical Outcome



AITL

BCL

AITL

BCL


1

Abruzzo LV (1993) [4]

46/M

LN

SK

26

Large-cell immunoblastic type

Cyclophosphamide

N/D

Died of multiorgan failure

2

Park S (2002) [5]

55/F

LN

LN

48

BCL

CHOP

CHOP-R

CR and alive 12 mo later

3

Xu Y (2002) [6]

48/F

LN

LN

0

DLBCL

CHOP and ESHAP

CR and relapsed a few months later

4

Zettl A (2002) [7]

68/M

LN

ST

34

DLBCL

Observation

Glucocorticoids

Died 4 mo later of tuberculosis

5

47/M

LN

LN

29

DLBCL

CC; BMT

CC; involved field radiation

Died 3 mo later of Aspergillus pneumonia

6

61/M

LN

LN

96

Plasmacytoma

N/Av

N/Av

Alive with disease 24 mo later

7

Hawley RC (2006) [8]

69/F

LN

SK

56

DLBCL

CHOP

R-hyperCVAD

Died 54 mo later

8

Attygalle AD (2007) [9]

28/M

LN

BM

24

DLBCL

CHOP

Gemcitabine

No response and died 3 mo later

9

60/F

LN

LN

8

DLBCL

CHOP

CHOP-Et

No response and died 3 mo later

10

59/M

LN

LN

8

DLBCL

N/Av

CC

PR and alive with disease 68 mo later

11

72/M

LN

LN

84

DLBCL

N/Av

N/Av

N/A

12

78/F

LN

LN

0

DLBCL

Thalidomide

PR

13

Willenbrock K (2007) [10]

76/F

LN

LN

8

DLBCL

N/Av

N/Av

N/Av

14

46/F

LN

BM

5

DLBCL

N/Av

N/Av

N/Av

15

84/M

LN

LN

0

DLBCL

N/Av

N/Av

N/Av

16

72/M

LN

LN

0

DLBCL

N/Av

N/Av

N/Av

17

65/M

LN

LN

0

CD30-positive BCL

N/Av

N/Av

N/Av

18

60/F

LN

LN

0

DLBCL

N/Av

N/Av

N/Av

19

Weisel KC (2008) [11]

59/M

LN

DB and lung

11

DLBCL

Fudarabine+ CHOP

N/D

Died 2 weeks later

20

Takahashi T (2010) [12]

66/F

LN

Ileum

24

DLBCL

THPCOP

CHASE

N/D

Died 1 mo later of respiratory failure

21

Skugor ND (2010) [13]

36/F

LN

LN

11

DLBCL

FED

CHOP-R and stem cell transplantation

CR

22

Huang J (2011) [14]

64/M

LN

LN

47

DLBCL

IHOP

CHOP-R

Alive with disease 13 mo later

23

Present case

65/M

LN

SK

19

DLBCL

CHOP

CHOP-R

PR


*, all B-cell lymphoma with EBV positive; AITL, angioimmunoblastic T-cell lymphoma; BCL, B-cell lymphoma; DLBCL, diffuse large B-cell lymphoma; LN, lymph node; SK, skin; ST, soft tissue; BM, bone marrow; DB, Duodenal bulbus; Interval 0, AITL with simultaneous B-cell lymphoma or primary B-cell lymphoma in the background of AITL; BMT, bone marrow transplantation; N/Av, not available; N/D, not done; PR, partial response; CR, complete remission; CHOP, cyclophosphamide, vincristine, adriamycin, and prednisone; ESHAP, etoposide, methyl prednisolone, cytarabine (ara-C) and cisplatin; hyperCVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; IHOP, ifosfamide, doxorubicin, vincristine, and prednisone; THPCOP, cyclophosphamide, pirarubicin, vincristine, prednisolone; CHASE, cyclophosphamide, cytarabine, etoposide, dexamethasone; FED, fludarabine, cyclophosphamide, dexamethasone; Et, etoposide; R, rituximab; CC, combination chemotherapy, details not available;

Yang et al. Diagnostic Pathology 2012 7:7   doi:10.1186/1746-1596-7-7

Open Data